Voyager Therapeutics, Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. Voyager is a pre-revenue biotechnology company developing AAV gene therapies and antibody programs for neurological diseases, including through its TRACER capsid platform. All figures below are in U.S. dollars; financial statement amounts are generally in millions unless noted.
Financial performance and position
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Collaboration revenue | $4.9 | $0.7 | $155.3 | $1.4 |
| Research and development expense | $22.0 | $12.5 | $40.6 | $26.9 |
| General and administrative expense | $8.3 | $7.6 | $17.3 | $15.2 |
| Net income (loss) | $(22.2) | $(19.1) | $101.8 | $(40.4) |
| Operating cash flow | Not presented separately | Not presented separately | $122.7 | $15.9 |
- First-half revenue and profit primarily reflect collaboration accounting events: $79.0 million related to Novartis option exercises and expiration of a third option, and $72.4 million under the 2023 Neurocrine agreement. These are not product sales; Voyager says it has generated no product revenue.
- Q2 operating loss was $25.4 million, compared with $19.4 million in Q2 2022. Q2 net loss widened to $22.2 million despite higher collaboration revenue; increased R&D spending and lower one-time benefits than in the prior-year period contributed.
- At June 30, cash and cash equivalents were $244.3 million and current marketable securities were $28.5 million, or approximately $272.7 million combined. Total assets were $315.5 million and stockholders’ equity was $199.0 million.
- The filing reports no borrowings or debt balance. Total liabilities were $116.5 million, including $83.0 million of deferred revenue and lease-related obligations. Current assets of $282.2 million exceeded current liabilities of $45.4 million.
- There is no meaningful product gross margin disclosed: the company remains pre-commercial and reports collaboration revenue rather than product sales.
Changes from the comparable period
- First-half collaboration revenue increased by $154.0 million year over year, largely from the Novartis and 2023 Neurocrine transactions. Q2 revenue rose $4.1 million year over year but remained modest compared with operating expenses.
- First-half R&D expense rose $13.7 million, primarily from higher staffing and external program costs, especially for anti-tau and ALS programs. First-half G&A increased $2.1 million.
- Cash, cash equivalents and restricted cash increased $145.4 million during the first half. Operating cash flow benefited from collaboration receipts and a $17.2 million increase in deferred revenue; it should not be read as recurring operating profitability.
- Common shares outstanding increased from 38.6 million at year-end 2022 to 43.8 million at June 30, 2023, including 4.4 million shares issued to Neurocrine. This represents meaningful shareholder dilution.
Outlook, agreements and risks
- Management expects available cash, cash equivalents and marketable securities, together with anticipated Neurocrine cost reimbursements, to fund planned operating expenses and capital expenditures into 2025. The company expects substantial future expenses and says additional funding or business-development transactions may be needed.
- For wholly owned programs, Voyager identified VY-TAU01 as its anti-tau lead candidate and expects an IND submission in the first half of 2024. It expects to select a lead SOD1 ALS candidate in the second half of 2023 and submit an IND in mid-2025. Both programs remain preclinical.
- The 2023 Neurocrine agreement covers GBA1 and three discovery programs. Neurocrine paid a $136.0 million upfront fee and purchased approximately $39.0 million of stock. The agreement includes substantial contingent development and commercial milestones and tiered royalties; these future amounts depend on development, regulatory and commercial outcomes and are not assured.
- Novartis exercised options for two undisclosed targets, generating a $25.0 million option fee in addition to recognition of previously deferred revenue. Novartis let a third target option expire, returning rights for that target to Voyager. Milestones and royalties on licensed products remain contingent.
- Key risks include clinical and preclinical failure, regulatory delays, dependence on collaborators and licensing revenue, potential need for further capital and dilution, manufacturing challenges, intellectual-property risks, and the uncertain timing and commercial potential of gene therapies. The filing reports no material pending legal proceedings and no material off-balance-sheet arrangements.
- Management stated that disclosure controls and procedures were effective as of June 30, 2023, and that there were no material changes in internal control over financial reporting during the first half.
Important facts for investors to verify
- How much of reported collaboration revenue and operating cash flow is nonrecurring license or option recognition versus continuing service reimbursements.
- Whether cash use, R&D spending and partner reimbursements support the stated runway into 2025, particularly if milestones or new transactions do not occur.
- Progress and timing against VY-TAU01 and SOD1 milestones, and the evidence supporting TRACER capsid safety, delivery and efficacy.
- The terms and economic implications of Neurocrine and Novartis agreements, including contingent milestones, royalties, termination rights and any cost-sharing options.
- The dilution impact of the Neurocrine stock issuance and outstanding equity awards; the filing lists 8.7 million potentially dilutive securities excluded from Q2 diluted loss-per-share calculations as anti-dilutive.
- The cash-flow discussion in MD&A refers to first-half net income of $101.6 million, while the financial statements report $101.8 million; investors should reconcile this apparent textual discrepancy with the filed statements.